BR Biopharma (NASDAQ:BRBI) Stock Price Crosses Below 200 Day Moving Average – What’s Next?

BR Biopharma, Inc. (NASDAQ:BRBI)’s share price passed below its two hundred day moving average during trading on Monday. The stock has a two hundred day moving average of $12.85 and traded as low as $9.14. BR Biopharma shares last traded at $9.84, with a volume of 20,882 shares trading hands.

Wall Street Analyst Weigh In

Separately, Weiss Ratings raised shares of BR Biopharma from a “sell (d-)” rating to a “sell (d)” rating in a report on Friday, October 2nd. One investment analyst has rated the stock with a Sell rating. Based on data from MarketBeat.com, the company currently has a consensus rating of “Sell”.

BR Biopharma Stock Down 34.7%

The company has a market capitalization of $116.21 million and a price-to-earnings ratio of 123.00. The stock’s 50-day simple moving average is $11.85 and its two-hundred day simple moving average is $12.85.

BR Biopharma (NASDAQ:BRBI) last posted its quarterly earnings data on Tuesday, June 30th. The company reported $0.09 EPS for the quarter. The firm had revenue of $25.13 million for the quarter.

BR Biopharma Cuts Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Friday, September 4th. Shareholders of record on Monday, August 17th were issued a $0.1415 dividend. This represents a $0.57 dividend on an annualized basis and a yield of 5.8%. The ex-dividend date was Monday, August 17th. This is a negative change from BR Biopharma’s previous quarterly dividend of $0.1470. BR Biopharma’s payout ratio is currently 525.00%.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in BR Biopharma stock. Acuitas Investments LLC bought a new stake in BR Biopharma, Inc. (NASDAQ:BRBI) during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 3,000 shares of the company’s stock, valued at approximately $45,000. BR Biopharma comprises 3.2% of Acuitas Investments LLC’s investment portfolio, making the stock its 7th biggest position.

BR Biopharma Company Profile

BRBI BR Partners SA, through its subsidiaries, operates as an investment bank which specializes in providing financial services for entrepreneurs and families principally in Brazil. It offers financial advisory services for mergers and acquisitions, capital markets, board services, shareholders, special situations and restructuring, pre-IPO, and privatization; and wealth management services. BRBI BR Partners SA is based in S?o Paulo, Brazil.